novo oral glp-1 Nordisk's Wegovy Pill Becomes First FDA-Approved Drug for Weight Loss Novo Nordisk's oral GLP-1 drug

Current therapeutic strategies in this domain are primarily stratified into four dimensions: pharmacological interventions targeting gut microbial metabolites 152 , dietary and nutritional interventions 108 , microecological modulation 9 , and postbiotic supplementation 108,153 (Table 2)

Dormancy Period: Up to 2 months

Under normal circumstances, the physical barrier of the intestinal epithelium allows small molecule nutrients such as water, electrolytes, and glucose to pass through, while preventing harmful substances such as bacteria, endotoxins, and food antigens from entering the body

Nano-sizing increases surface area on the cell, making it more bioavailable